TICKERNOMICS Sign up
Last Update: 2024-12-27 15:25:25
Arbutus Biopharma Corp ( ABUS ) https://www.arbutusbio.com
3.19USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
ABUS
25.59%
SPY
32.66%
-16.49%
ABUS
SPY
108.59%
ABUS
28.11%
SPY
302.52%
-77.05%
ABUS
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
602.90
476.55
0.79
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-7.86
89.42
5.64
-9.53
0.00
-5.78
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-1601.19
100.00
-1388.86
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
10.6864
-238.77
-58.93
1.73
Other Earnings and Cash Flow Stats:
Arbutus Biopharma Corp ( ABUS ) Net Income TTM ($MM) is -76.70
Arbutus Biopharma Corp ( ABUS ) Operating Income TTM ($MM) is -82.91
Arbutus Biopharma Corp ( ABUS ) Owners' Earnings Annual ($MM) is 0.00
Arbutus Biopharma Corp ( ABUS ) Current Price to Owners' Earnings ratio is 0.00
Arbutus Biopharma Corp ( ABUS ) EBITDA TTM ($MM) is -81.50
Arbutus Biopharma Corp ( ABUS ) EBITDA Margin is -1388.86%
Capital Allocation:
Arbutus Biopharma Corp ( ABUS ) has paid 0.00 dividends per share and bought back -21.484486 million shares in the past 12 months
Arbutus Biopharma Corp ( ABUS ) has reduced its debt by 0.463 million USD in the last 12 months
Capital Structure:
Arbutus Biopharma Corp ( ABUS ) Interest-bearing Debt ($MM) as of last quarter is 1
Arbutus Biopharma Corp ( ABUS ) Annual Working Capital Investments ($MM) are -17
Arbutus Biopharma Corp ( ABUS ) Book Value ($MM) as of last quarter is 106
Arbutus Biopharma Corp ( ABUS ) Debt/Capital as of last quarter is 1%
Other Balance Sheet Stats:
Arbutus Biopharma Corp ( ABUS ) has 31 million in cash on hand as of last quarter
Arbutus Biopharma Corp ( ABUS ) has 18 million of liabilities due within 12 months, and long term debt 0 as of last quarter
Arbutus Biopharma Corp ( ABUS ) has 189 common shares outstanding as of last quarter
Arbutus Biopharma Corp ( ABUS ) has 0 million USD of preferred stock value
Academic Scores:
Arbutus Biopharma Corp ( ABUS ) Altman Z-Score is -3.47 as of last quarter
Arbutus Biopharma Corp ( ABUS ) Piotroski Score is 4.00 as of last quarter
Corporate Governance:
Arbutus Biopharma Corp ( ABUS ) largest shareholder is owning shares at 0.00 ($MM) value
MANCHESTER KEITH S(an insider) Sold 8846 shares of Arbutus Biopharma Corp ( ABUS ) for the amount of $32637.32 on 2024-08-14
22.22% of Arbutus Biopharma Corp ( ABUS ) is held by insiders, and 51.56% is held by institutions
Arbutus Biopharma Corp ( ABUS ) went public on 2015-08-03
Other Arbutus Biopharma Corp ( ABUS ) financial metrics:
FCF:-70.96
Unlevered Free Cash Flow:0.00
EPS:-0.42
Operating Margin:-1601.19
Gross Profit Margin:100.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-73.78
Beta:1.73
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Arbutus Biopharma Corp ( ABUS ) :
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-161, an oral HBV RNA destabilizer; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate AB-729. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.